Post by
prophetoffactz on Apr 29, 2024 11:52am
PGX partnership
What could a PGX deal look like now with completion of the 5X PGX scale-up and Health Canada approval for first commercial sales, and commissioning of the 10X PGX scale-up expected in 5 months with industry leader Natex? CZO may have de-risked PGX from requiring 100X scale-up to requiring only 10X scale-up to reach 1000L large scale-commercial production and has Natex by its side. In moving from 10L to 100L CZO/Natex will have just demonstrated a 10X scale-up to small-scale commercial production.
CZO will also be able to negotiate a PGX deal in a position of strength with the material capital and resources of AEZS and, potentially, with the relationship with Bloom Burton, etc.
PGX-YBG/Fibrosis data has also been submitted for publishing after Dr. Martin Kolb said that if preclinical results are replicated in humans it could profoundly change the treatment landscape.
Last AGM the following was said about PGX:
CZO has shown 2X CoQ10 bioavailability of cyclodextrine and 4X bioavailability of Triolien. Discussions concerning out-licensing a PGX complex are underway right now with serious potential partners in the neutraceutical industry. Partners are pretty impressed and understand why CZO wants to make bioavailability the unique selling point. Sigrun Watson is holding discussions with very, very serious partners. The goal is still a license by the end of the year. CoQ10 is a $4 billion market.